SEARCH

SEARCH BY CITATION

References

  • Agarwal, B. & Naresh, K.N. (2002) Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: study of 116 cases. American Journal of Hematology, 70, 278282.
  • Bastion, Y., Sebban, C., Berger, F., Felman, P., Salles, G., Dumontet, C., Bryon, P.A. & Coiffier, B. (1997) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. Journal of Clinical Oncology, 15, 15871594.
  • Chau, I., Jones, R., Cunningham, D., Wotherspoon, A., Maisey, N., Norman, A.R., Jain, P., Bishop, L., Horwich, A. & Catovsky, D. (2003) Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? British Journal of Cancer, 89, 3642.
  • Cho-Vega, J.H., Rassidakis, G.Z., Admirand, J.H., Oyarzo, M., Ramalingam, P., Paraguya, A., McDonnell, T.J., Amin, H.M. & Medeiros, L.J. (2004) MCL-1 expression in B-cell non-Hodgkin's lymphomas. Human Pathology, 35, 10951100.
  • Dardick, I. & Caldwell, D.R. (1986) Follicular center cell lymphoma. Morphologic data relating to observer reproducibility. Cancer, 58, 24772484.
  • Gascoyne, R.D., Adomat, S.A., Krajewski, S., Krajewska, M., Horsman, D.E., Tolcher, A.W., O'Reilly, S.E., Hoskins, P., Coldman, A.J., Reed, J.C. & Connors, J.M. (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood, 90, 244251.
  • Khoury, J.D., Medeiros, L.J., Rassidakis, G.Z., McDonnell, T.J., Abruzzo, L.V. & Lai, R. (2003) Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. Journal of Pathology, 199, 9097.
  • McDonnell, T.J. & Korsmeyer, S.J. (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature, 349, 254256.
  • Michels, J., O'Neill, J.W., Dallman, C.L., Mouzakiti, A., Habens, F., Brimmell, M., Zhang, K.Y., Craig, R.W., Marcusson, E.G., Johnson, P.W. & Packham, G. (2004) Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene, 23, 48184827.
  • Nathwani, B.N., Harris, N.L., Weisenburger, D., Isaacson, P.G., Piris, M.A., Berger, F., Muller-Hermelink, H.K. & Swerdlow, S.H. (2001) Pathology and genetics of tumors of haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumors. Follicular Lymphoma (ed. by E.S.Jaffe, N.L.Harris, H.Stein & J.W.Vardiman), pp. 162167. IARC Press, Lyon.
  • Zhang, C.L., Kamarashev, J., Qin, J.Z., Burg, G., Dummer, R. & Dobbeling, U. (2003) Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. Journal of Pathology, 200, 249254.
  • Zhou, P., Levy, N.B., Xie, H., Qian, L., Lee, C.Y., Gascoyne, R.D. & Craig, R.W. (2001) MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood, 97, 39023909.